Assessment scale studies for MCI and early AD clinical trials

 
   Lead Investigator:    Wenjia Wang
   Institution      :    Univerist?? de Bordeaux / Pharnext
   E-Mail           :    wwang@pharnext.com
   Proposal ID      :    574



   Proposal Description:
   Recent research suggests that AD begins many years before the symptoms such as    memory loss or behavioral changes appear.  If AD can be detected earlier, there                                                                                   may be a better chance that treatment to become successful. However, the most     used assessment scales have their limits. For example, ADAS cog11 is not          sensitive enough to detect changes in predementia stages CDR-SB doesn???t have    generally accepted clinical endpoints. A new clinical assessment scale which is                                                                                  reliable and sensitive, especially in MCI and early AD stages would be needed.    Our aim is to develop a new composite score which is sensitive to AD              progression based on existing sub items. We will examine the sensitivity of       each sub item in the assessment s scales often used in AD trials and select the                                                                                   tops for a composite score.  This score could be used as a clinical endpoint to                                                                                   design more efficient trials to screen potential treatments for early signs of    efficacy.